Trial Profile
PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2023
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms PREDICT UC
- 06 Feb 2023 Status changed from active, no longer recruiting to completed.
- 12 Oct 2021 Planned End Date changed from 1 Jan 2022 to 1 Oct 2022.
- 12 Oct 2021 Planned primary completion date changed from 1 Jan 2022 to 1 Dec 2021.